Receive Information

Antisense Therapeutics Ltd (ASX: ANP)

  • Antisense Therapeutics Ltd (ASX:ANP) is an Australian publicly traded biopharmaceutical development company. The Company’s R&D activities are focused on developing and commercialising antisense drugs acquired from Ionis Pharmaceuticals Inc (NASDAQ:IONS), acknowledged world leaders in antisense drug development.
     
  • The Company has an advanced stage product development pipeline with 2 compounds that have delivered positive Phase II clinical trial results; ATL1103, in development for the orphan disease acromegaly and ATL1102 for Multiple Sclerosis.  The Company recently received Orphan Drug designation in both the US and Europe for ATL1103 for acromegaly.